Geulah Livshits

Stock Analyst at Chardan Capital

(0)
# 4842
Out of 5,356 analysts
219
Total ratings
30.11%
Success rate
-22.68%
Average return
35 Stocks
Name Action PT Current % Upside Ratings Updated
TSHA Taysha Gene Therapie...
Maintains: Strong Buy
7 9
2.9 210.34% 13 May 29, 2025
RCKT Rocket Pharmaceutica...
Maintains: Buy
46 17
2.97 472.39% 18 May 28, 2025
PRME Prime Medicine
Maintains: Buy
16 12
1.61 645.34% 5 May 19, 2025
SLDB Solid Biosciences
Maintains: Buy
16 15
4.57 228.23% 7 May 19, 2025
IPSC Century Therapeutics
Maintains: Buy
7 6
0.62 867.74% 6 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
13 12
1.77 577.97% 6 May 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
22 20
3.82 423.56% 9 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
28 25
4.15 502.41% 9 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
30 25
1.95 1182.05% 12 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
68 68
8.14 735.38% 14 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
9 9
0.6 1400% 11 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
219 219
135.63 61.47% 10 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
84 82
40.96 100.2% 13 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
13 13
2.24 480.36% 11 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
12 12
3.74 220.86% 8 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
24.35 105.34% 1 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 6
0.43 1295.35% 4 Mar 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 10 Dec 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
11 6
n/a n/a 5 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
41 41
5.87 598.47% 4 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
28 25
6.18 304.53% 2 Mar 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
12
2.34 412.82% 4 Mar 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
30 25
n/a n/a 4 Mar 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
191 208
26.99 670.66% 7 Jan 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
160 40
n/a n/a 3 Dec 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
15 16
1.71 835.67% 4 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 3
6.68 -62.57% 5 Aug 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
450 270
n/a n/a 2 Feb 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
100 90
9.26 871.92% 1 Nov 3, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
6 4
3.58 11.73% 3 Nov 3, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
n/a n/a 1 Oct 1, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
660 600
0.05 1199900% 2 Aug 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
50 30
2.77 983.03% 1 Jul 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
9.33 92.93% 1 Oct 27, 2020